These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36610263)

  • 21. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
    Naqvi MF; Vo HH; Vining D; Tsimberidou AM
    Ther Adv Med Oncol; 2021; 13():17588359211001538. PubMed ID: 33995588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
    Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
    Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
    [No Abstract]   [Full Text] [Related]  

  • 25. Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
    Marsavela G; McEvoy AC; Pereira MR; Reid AL; Al-Ogaili Z; Warburton L; Khattak MA; Abed A; Meniawy TM; Millward M; Ziman MR; Calapre L; Gray ES
    Br J Cancer; 2022 Feb; 126(3):401-408. PubMed ID: 34373567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study.
    Li M; Hou X; Zheng L; Ma Y; Li D; Lv Y; Chen J; Zheng W; Shao Y; Mou Y; Chen L
    ESMO Open; 2022 Feb; 7(1):100305. PubMed ID: 34922300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer.
    Zou D; Day R; Cocadiz JA; Parackal S; Mitchell W; Black MA; Lawrence B; Fitzgerald S; Print C; Jackson C; Guilford P
    Carcinogenesis; 2020 Nov; 41(11):1507-1517. PubMed ID: 32955091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
    Hrebien S; Citi V; Garcia-Murillas I; Cutts R; Fenwick K; Kozarewa I; McEwen R; Ratnayake J; Maudsley R; Carr TH; de Bruin EC; Schiavon G; Oliveira M; Turner N
    Ann Oncol; 2019 Jun; 30(6):945-952. PubMed ID: 30860573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RECIST - learning from the past to build the future.
    Litière S; Collette S; de Vries EG; Seymour L; Bogaerts J
    Nat Rev Clin Oncol; 2017 Mar; 14(3):187-192. PubMed ID: 27995946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.
    Pietrasz D; Wang-Renault S; Taieb J; Dahan L; Postel M; Durand-Labrunie J; Le Malicot K; Mulot C; Rinaldi Y; Phelip JM; Doat S; Blons H; de Reynies A; Bachet JB; Taly V; Laurent-Puig P
    Br J Cancer; 2022 Feb; 126(3):440-448. PubMed ID: 34811505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
    Gafita A; Rauscher I; Fendler WP; Murthy V; Hui W; Armstrong WR; Herrmann K; Weber WA; Calais J; Eiber M; Weber M; Benz MR
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4271-4281. PubMed ID: 35767071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
    Sahin IH; Lin Y; Yothers G; Lucas PC; Deming D; George TJ; Kopetz S; Lieu CH; Dasari A
    Oncology (Williston Park); 2022 Oct; 36(10):604-608. PubMed ID: 36260786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
    Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
    Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
    Bratman SV; Yang SYC; Iafolla MAJ; Liu Z; Hansen AR; Bedard PL; Lheureux S; Spreafico A; Razak AA; Shchegrova S; Louie M; Billings P; Zimmermann B; Sethi H; Aleshin A; Torti D; Marsh K; Eagles J; Cirlan I; Hanna Y; Clouthier DL; Lien SC; Ohashi PS; Xu W; Siu LL; Pugh TJ
    Nat Cancer; 2020 Sep; 1(9):873-881. PubMed ID: 35121950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
    Lee JH; Long GV; Boyd S; Lo S; Menzies AM; Tembe V; Guminski A; Jakrot V; Scolyer RA; Mann GJ; Kefford RF; Carlino MS; Rizos H
    Ann Oncol; 2017 May; 28(5):1130-1136. PubMed ID: 28327969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
    BJU Int; 2021 Jan; 127(1):90-95. PubMed ID: 32662189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted mutation detection in breast cancer using MammaSeq™.
    Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
    Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
    Darrigues L; Pierga JY; Bernard-Tessier A; Bièche I; Silveira AB; Michel M; Loirat D; Cottu P; Cabel L; Dubot C; Geiss R; Ricci F; Vincent-Salomon A; Proudhon C; Bidard FC
    Breast Cancer Res; 2021 Mar; 23(1):31. PubMed ID: 33676547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.